Analyst Reiterates Buy Rating on ZyVersa Therapeutics with Revised Price Target
On March 12, 2024, analyst Ed Arce from HC Wainwright & Co. reiterated his Buy rating on ZyVersa Therapeutics (NASDAQ: ...
Tag: ZVSA
Developing a Promising Therapeutic Option for ObesityRelated Inflammation Inflammasome ASC Inhibitor IC 100
Obesity is a prevalent global issue, affecting millions of individuals worldwide. It is characterized by chronic inflammation, which can lead ...
ZyVersa Therapeutics Makes Stunning Comeback After Trading Halt
On February 26, 2024, ZyVersa Therapeutics made a remarkable comeback as trading resumed following a circuit breaker halt, resulting in ...
Unveiling the Role of Inflammation and ASC Specks in Neurological Diseases A Milestone in Therapeutic Advancements
On February 14, 2024, a groundbreaking review article was unveiled by ZyVersa Therapeutics, shedding light on a crucial aspect of ...
Inflammasome Activation Linked to Brain Metastasis in TripleNegative Breast Cancer
On January 17, 2024, ZyVersa Therapeutics, Inc. shed light on a groundbreaking study that establishes a connection between inflammasome activation ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
